Kaijie He

ORCID: 0000-0001-8866-1994
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Cells and Metastasis
  • Cancer Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Computational Drug Discovery Methods
  • Science, Research, and Medicine
  • Microtubule and mitosis dynamics
  • Parkinson's Disease Mechanisms and Treatments
  • Telomeres, Telomerase, and Senescence
  • CAR-T cell therapy research
  • Chemical Reactions and Isotopes
  • Immune Cell Function and Interaction
  • RNA Interference and Gene Delivery
  • Cancer Genomics and Diagnostics
  • Advanced Neural Network Applications
  • Lymphoma Diagnosis and Treatment
  • Glycosylation and Glycoproteins Research
  • Cell Image Analysis Techniques
  • Video Surveillance and Tracking Methods
  • Radiation Therapy and Dosimetry
  • Child and Adolescent Psychosocial and Emotional Development
  • Nuclear Receptors and Signaling
  • Neurogenetic and Muscular Disorders Research
  • Cerebrospinal fluid and hydrocephalus
  • Rough Sets and Fuzzy Logic
  • Text and Document Classification Technologies

Second Affiliated Hospital of Soochow University
2023

Soochow University
2020-2023

Guangxi Normal University
2023

Jiangsu Hengrui Medicine (China)
2019

University of Southern California
2009-2013

USC Norris Comprehensive Cancer Center
2010

Most deep trackers still follow the guidance of siamese paradigms and use a template that contains only target without any contextual information, which makes it difficult for tracker to cope with large appearance changes, rapid movement, attraction from similar objects. To alleviate above problem, we propose long-term context attention (LCA) module can perform extensive information fusion on its frames, calculate correlation while enhancing features. The complete location as well state...

10.1609/aaai.v37i1.25155 article EN Proceedings of the AAAI Conference on Artificial Intelligence 2023-06-26

Cancer initiation and progression have been attributed to newly discovered subpopulations of self-renewing, highly tumorigenic, drug-resistant tumor cells termed cancer stem cells. Recently, we others reported a new phenotypic plasticity wherein cell populations could arise not only from pre-existing stem-like but also lacking these properties. In the current study, hypothesized that this newfound may be mediated by PI3K/Akt Wnt/β-catenin signaling, pathways previously implicated in...

10.1002/ijc.28341 article EN International Journal of Cancer 2013-06-20

Abstract Drug resistance and brisk tumor initiation have traditionally been viewed as preexisting phenotypes present in small subpopulations of neoplastic cells sometimes termed cancer stem cells. However, recent work cell lines has shown that drug-resistant tumor-initiating features can emerge de novo within fractionated initially lacking these phenotypes. In the study, we asked whether such phenotypic plasticity exists broadly unperturbed xenografts growing spontaneously without...

10.1158/1535-7163.mct-10-1120 article EN Molecular Cancer Therapeutics 2011-04-26

Abstract Interleukin 12 (IL-12) is a cytokine that able to activate both innate (NK cells) and adaptive (T immunities, making it an ideal candidate for immuno-oncology therapy. Administration of IL-12 drugs locally has shown promising clinical results in treating tumors. However, when applying systemically, severe dose-limiting toxicities are induced, greatly impeding the drug development process its potential cancer treatment. Herein, we designed IBI3026, immune agonist targets receptor...

10.1158/1538-7445.am2025-3118 article EN Cancer Research 2025-04-21

Abstract Inhibition of EGFR signaling is clinically effective in colorectal cancer (CRC) as evidenced by the approval for Cetuximab combination with chemotherapy or Encorafenib, a BRAF inhibitor, and promising clinical results when combined KRAS inhibitors, such Adagrasib Sotorasib. This underscores versatility antibodies. However, these strategies are inevitably associated high target-related toxicities, which limit maximal potential drugs. Here, we designed IBI3019, next-generation blocker...

10.1158/1538-7445.am2025-4249 article EN Cancer Research 2025-04-21

Abstract Despite the revolution of therapeutic landscape for solid tumors advanced by immune checkpoint inhibitors (ICIs), primary or acquired resistance to ICI remain major unmet medical challenges in substantial proportion patients. Activation antigen presentation and priming may provide feasible solution insufficiency endogenous anti-tumor activity ICI-resistant cover multiple types cold tumors. Here we report first disclosure preclinical data IAR037, a novel CD40/PD-L1 bispecific...

10.1158/1538-7445.am2025-lb139 article EN Cancer Research 2025-04-25

Parkinson's disease (PD) is characterized by the irreversible loss of dopaminergic neurons and accumulation α-synuclein in Lewy bodies. The oligomeric (O-αS) most toxic form species, it has been reported to be a robust inflammatory mediator. Mutations Leucine-Rich Repeat Kinase 2 (LRRK2) are also genetically linked PD neuroinflammation. However, how O-αS LRRK2 interact glial cells remains unclear. Here, we that G2019S mutation, which one frequent causes familial PD, enhanced effects on...

10.1016/j.isci.2023.108130 article EN cc-by iScience 2023-10-05

Cancer progenitor cells (CPCs) have been postulated to promote treatment resistance and disease progression in prostate other malignancies. We investigated whether the enzyme telomerase, which is active cancer normal stem cells, plays an important role CPC can be exploited neutralize these cells.We used flow cytometry assays of gene expression, clonogenicity, invasiveness isolate characterize a putative subpopulation from freshly resected human prostatectomy specimens. Telomerase activity...

10.1002/pros.21355 article EN The Prostate 2011-02-14

Although inhibiting EGFR-mediated signaling proved to be effective in treating certain types of cancers, a quickly evolved mechanism that either restores the EGFR or activates an alternative pathway for driving proliferation and survival malignant cells limits efficacy utility approach via suppressing functionality. Given fact overexpression is commonly seen many EGFR-targeting antibody-drug conjugate (ADC) can selectively kill cancer independently blocking signaling. Herein, we describe...

10.1158/1535-7163.mct-18-0854 article EN Molecular Cancer Therapeutics 2019-04-08

Previous investigations have suggested that decreased expression of glutamate transporter-1 (GLT-1) is involved in excitotoxicity and contribute to the development Parkinson's disease (PD), GLT-1 animal models PD. mainly expressed astrocytes, striatum a GLT-1-rich brain area.The aim was explore function mechanism astrocytic PD-like changes.In study, changes their molecular rodents were tested by behavioral assessment, micro-positron emission tomography/computed tomography (PET/CT), western...

10.3233/jpd-212640 article EN Journal of Parkinson s Disease 2021-10-26

Abstract Early-life stress (ELS) can cause long-term effects on human health, ranging from adolescence to adulthood, and even gerontic. Although clinical retrospective data suggest that ELS may be related senile neurodegenerative diseases such as Parkinson’s disease (PD), there are few prospective investigations explore its real contribution PD. Here, we investigated the behavioral, histochemical, neuromorphological, transcriptional changes induced by maternal separation (MS), an model....

10.1093/gerona/glab253 article EN The Journals of Gerontology Series A 2021-08-27

Abstract Claudin18.2 is important for the formation and function of tight junctions between cells in epithelial tissues. Normally expressed only gastric mucosa, overexpressed multiple types solid tumors, including gastric, pancreatic, breast colon cancers. Despite being a well-established tumor-associated antigen, clinical value feasibility targeting by various modalities are yet-to-be fully demonstrated. IBI343 humanized anti-Claudin18.2 monoclonal antibody conjugated to Exatecan via...

10.1158/1538-7445.am2024-lb057 article EN Cancer Research 2024-04-05

Abstract B7-H3 and EGFR are both clinically validated TAAs in solid tumors. We previously demonstrated IBI334 (B7-H3/EGFR bsAb) study that (1) co-expressed multiple tumors; (2) B7-H3-aided signaling inhibition was significantly more potent than Zalutumumab (EGFR mAb) Amivantamab (c-met/EGFR bsAb); (3) has favorable safety profile cynomolgus monkey at 120 mg/kg/week. Building on this optimized bispecific antibody, we site-specifically conjugated with Exatecan (drug-antibody-ratio = 4) using...

10.1158/1538-7445.am2024-lb055 article EN Cancer Research 2024-04-05

<h3>Background</h3> Low-dose-IL-2 (LDIL-2) is shown to be a promising treatment for multiple autoimmune diseases by stimulating regulatory T (Treg) cells. Challenges such as small therapeutic window, poor developability and inconvenient dosing schedule have limited the utilization of LDIL-2 in clinic. <h3>Methods</h3> Wild type IL-2 (IL-2<sup>WT</sup>) has thermal stability high aggregation tendency vivo, resulting PK immunogenicity. To address this issue, we examined structural similarity...

10.1136/jitc-2024-sitc2024.0946 article EN cc-by-nc Regular and Young Investigator Award Abstracts 2024-11-01

Most deep trackers still follow the guidance of siamese paradigms and use a template that contains only target without any contextual information, which makes it difficult for tracker to cope with large appearance changes, rapid movement, attraction from similar objects. To alleviate above problem, we propose long-term context attention (LCA) module can perform extensive information fusion on its frames, calculate correlation while enhancing features. The complete location as well state...

10.48550/arxiv.2302.13840 preprint EN other-oa arXiv (Cornell University) 2023-01-01

&lt;div&gt;Abstract&lt;p&gt;Drug resistance and brisk tumor initiation have traditionally been viewed as preexisting phenotypes present in small subpopulations of neoplastic cells sometimes termed cancer stem cells. However, recent work cell lines has shown that drug-resistant tumor-initiating features can emerge &lt;i&gt;de novo&lt;/i&gt; within fractionated initially lacking these phenotypes. In the study, we asked whether such phenotypic plasticity exists broadly unperturbed xenografts...

10.1158/1535-7163.c.6535317 preprint EN 2023-04-03
Coming Soon ...